Active, not recruitingPhase 3NCT07098897

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The Affiliated Hospital of Xuzhou Medical University
Intervention
Telitacicept 160mg(drug)
Enrollment
150 enrolled
Eligibility
18-75 years · All sexes
Timeline
2024 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07098897 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials